



November 30, 2023

Launch of UPLIZNA® for Neuromyelitis Optica Spectrum Disorder in Taiwan

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereinafter, “MTPC”), a member of the Mitsubishi Chemical Group, announced a today that Tai Tien Pharmaceuticals Co., Ltd. (Head Office: Taipei, Taiwan; General Manager Tony Chu; hereinafter, “Tai Tien”), which is a consolidated subsidiary of MTPC, has launched UPLIZNA® for Intravenous Infusion 100mg (UPLIZNA®, generic name: inebilizumab (genetically modified), Japanese name: UPLIZNA® for I.V. Infusion 100mg) as a treatment agent used to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive in Taiwan.

MTPC licensed this product* from Amgen (Headquarters: California, USA) in October 2019. In Taiwan, NMOSD was designated as a rare disease in November 2021. MTPC received import and marketing approval for UPLIZNA® in September 2022 and have been preparing for its launch.

UPLIZNA® has not only a new mechanism of action for NMOSD, but also a convenient dosing interval of once every six months, that enables treatment tailored to the lifestyle of patients. Tai Tien will strengthen its business base through further expansion of the product lineup in the central nervous system disease area and offer UPLIZNA® as a new treatment option for NMOSD patients in the relapse prevention period.

MTPC has received approval of UPLIZNA® for the treatment of NMOSD in Japan in March 2021 and has launched it in June 2021.

MTPC will continue to contribute to improving the quality of life of patients by delivering treatment options to patients fighting against NMOSD.

*formerly Viela Bio/Horizon Therapeutics which was acquired by Amgen.

<p><i>Contact:</i> Mitsubishi Chemical Group Corporation Corporate Communications Division Osaka Corporate Communications Department +81-6-6205-5119</p>
--

■ **About UPLIZNA®**

UPLIZNA® is a humanized anti-CD19 monoclonal antibody. It binds to a protein called CD19 which is expressed on B cells including antibody-producing plasmablasts and plasma cells, and rapidly depletes these cells from circulation. For the treatment of NMOSD, Amgen has received approval for UPLIZNA® in the US and EU, and its partner has received approval in China.

■ **About Tai Tien Pharmaceuticals Co., Ltd. (Tai Tien)**

Tai Tien Pharmaceuticals was established in Taipei in 1987 and focuses on the field of lifestyle-related diseases with products such as HERBESSER®, CONCOR® (Japan name: Maintate®), LIVALO®, and CANAGLU®. In addition, Tai Tien is contributing to the treatment of patients with autoimmune diseases in Taiwan with the launches of SIMPONI® and REMICADE®.